ATE326462T1 - Pyrazolverbindungen als protein-kinase- inhibitoren - Google Patents

Pyrazolverbindungen als protein-kinase- inhibitoren

Info

Publication number: ATE326462T1
Authority: AT; Austria
Prior art keywords: protein kinase; kinase inhibitors; pyrazole compounds; pyrazole; compounds
Prior art date: 2000-12-21

Application number

AT01994510T

Other languages

English (en)

Inventor

David Bebbington

Jean-Damien Charrier

Julian M C Golec

Andrew Miller

Ronald Knegtel

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-21

Filing date

2001-12-19

Publication date

2006-06-15

2001-12-19 Application filed by Vertex Pharma filed Critical Vertex Pharma

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE326462T1 publication Critical patent/ATE326462T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Emergency Medicine (AREA)

AT01994510T 2000-12-21 2001-12-19 Pyrazolverbindungen als protein-kinase- inhibitoren ATE326462T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25788700P	2000-12-21	2000-12-21
US28694901P	2001-04-27	2001-04-27

Publications (1)

Publication Number	Publication Date
ATE326462T1 true ATE326462T1 (de)	2006-06-15

Family

ID=26946273

Family Applications (9)

Application Number	Title	Priority Date	Filing Date
AT01994510T ATE326462T1 (de)	2000-12-21	2001-12-19	Pyrazolverbindungen als protein-kinase- inhibitoren
AT01993360T ATE326461T1 (de)	2000-12-21	2001-12-19	Pyrazolverbindungen als proteinkinasehemmer
AT01271061T ATE327989T1 (de)	2000-12-21	2001-12-19	Pyrazolverbindungen als protein-kinase- inhibitoren
AT01985059T ATE326460T1 (de)	2000-12-21	2001-12-19	Pyrazolverbindungen als proteinkinasehemmer
AT01994323T ATE340172T1 (de)	2000-12-21	2001-12-19	Pyrazolverbindungen als protein- kinasehemmer
AT01273861T ATE354573T1 (de)	2000-12-21	2001-12-19	ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
AT06011799T ATE528303T1 (de)	2000-12-21	2001-12-19	Pyrazoleverbindungen als proteinkinasehemmer
AT01994347T ATE326463T1 (de)	2000-12-21	2001-12-20	Pyrazolverbindungen als protein-kinasehemmer
AT01991439T ATE353890T1 (de)	2000-12-21	2001-12-20	Pyrazolverbindungen als proteinkinasehemmer

Family Applications After (8)

Application Number	Title	Priority Date	Filing Date
AT01993360T ATE326461T1 (de)	2000-12-21	2001-12-19	Pyrazolverbindungen als proteinkinasehemmer
AT01271061T ATE327989T1 (de)	2000-12-21	2001-12-19	Pyrazolverbindungen als protein-kinase- inhibitoren
AT01985059T ATE326460T1 (de)	2000-12-21	2001-12-19	Pyrazolverbindungen als proteinkinasehemmer
AT01994323T ATE340172T1 (de)	2000-12-21	2001-12-19	Pyrazolverbindungen als protein- kinasehemmer
AT01273861T ATE354573T1 (de)	2000-12-21	2001-12-19	ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
AT06011799T ATE528303T1 (de)	2000-12-21	2001-12-19	Pyrazoleverbindungen als proteinkinasehemmer
AT01994347T ATE326463T1 (de)	2000-12-21	2001-12-20	Pyrazolverbindungen als protein-kinasehemmer
AT01991439T ATE353890T1 (de)	2000-12-21	2001-12-20	Pyrazolverbindungen als proteinkinasehemmer

Country Status (28)

Country	Link
US (16)	US6664247B2 (de)
EP (10)	EP1345925B1 (de)
JP (19)	JP4160392B2 (de)
KR (8)	KR100909665B1 (de)
CN (6)	CN100340555C (de)
AP (2)	AP2003002825A0 (de)
AR (4)	AR040925A1 (de)
AT (9)	ATE326462T1 (de)
AU (7)	AU2002255452B2 (de)
BR (2)	BR0116411A (de)
CA (8)	CA2432303C (de)
CY (1)	CY1106297T1 (de)
DE (8)	DE60119774T2 (de)
DK (3)	DK1353916T3 (de)
ES (7)	ES2272567T3 (de)
HK (8)	HK1059776A1 (de)
HU (5)	HUP0400908A3 (de)
IL (8)	IL156407A0 (de)
MX (8)	MXPA03005609A (de)
MY (1)	MY140377A (de)
NO (5)	NO20032671L (de)
NZ (8)	NZ526468A (de)
PL (2)	PL210414B1 (de)
PT (3)	PT1355905E (de)
RU (1)	RU2355688C2 (de)
SI (2)	SI1353916T1 (de)
TW (2)	TWI290551B (de)
WO (8)	WO2002059111A2 (de)

Families Citing this family (374)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982260B1 (en)	1999-11-22	2006-01-03	Warner-Lambert Company	Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
KR100896664B1 (ko) *	2000-09-15	2009-05-14	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피라졸 화합물
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
CA2430539C (en) *	2000-12-05	2010-07-13	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
ATE326462T1 (de)	2000-12-21	2006-06-15	Vertex Pharma	Pyrazolverbindungen als protein-kinase- inhibitoren
PT1370553E (pt) *	2001-03-23	2006-09-29	Bayer Corp	Inibidores de rhoquinase
AU2002252614B2 (en)	2001-04-10	2006-09-14	Merck Sharp & Dohme Corp.	Inhibitors of Akt activity
US7105667B2 (en) *	2001-05-01	2006-09-12	Bristol-Myers Squibb Co.	Fused heterocyclic compounds and use thereof
US7138404B2 (en) *	2001-05-23	2006-11-21	Hoffmann-La Roche Inc.	4-aminopyrimidine derivatives
US7115617B2 (en)	2001-08-22	2006-10-03	Amgen Inc.	Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en)	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
WO2003026664A1 (en) *	2001-09-26	2003-04-03	Bayer Corporation	2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
EP1820503B1 (de)	2001-09-26	2012-02-22	Pfizer Italia S.r.l.	Als Kinaseinhibitoren aktive Aminoindazol-Derivate, Herstellungsverfahren dafür und pharmazeutische Zusammensetzungen damit
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
WO2003055866A1 (en) *	2001-12-21	2003-07-10	Bayer Pharmaceuticals Corporation	Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
DE60325551D1 (de)	2002-01-10	2009-02-12	Hoffmann La Roche	Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
EP1472245A2 (de) *	2002-02-06	2004-11-03	Vertex Pharmaceuticals Incorporated	Heteroaryl-verbindungen und ihre anwendung als gsk-3-hemmer
EP1485100B1 (de)	2002-03-15	2010-05-05	Vertex Pharmaceuticals Incorporated	Azolylaminoazine als proteinkinasehemmer
EP1485380B1 (de) *	2002-03-15	2010-05-19	Vertex Pharmaceuticals Incorporated	Azolylaminoazine als proteinkinasehemmer
DE60327999D1 (de)	2002-03-15	2009-07-30	Vertex Pharma	Azolylaminoazine als inhibitoren von proteinkinasen
WO2003086394A1 (en)	2002-04-08	2003-10-23	Merck & Co., Inc.	Inhibitors of akt activity
US7524852B2 (en)	2002-06-07	2009-04-28	Kyowa Hakko Kogyo Co., Ltd.	Bicyclic pyrimidine derivatives
MY141867A (en) *	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
EP1551841A1 (de) *	2002-07-23	2005-07-13	SmithKline Beecham Corporation	Pyrazolopyrimidine als kinaseinhibitoren
WO2004014382A1 (en)	2002-07-29	2004-02-19	Rigel Pharmaceuticals	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2494100C (en) *	2002-08-02	2011-10-11	Vertex Pharmaceuticals Incorporated	Pyrazole compositions useful as inhibitors of gsk-3
SI1532145T1 (sl) *	2002-08-02	2007-02-28	Vertex Pharma	Pirazolni sestavki, koristni kot inhibitorji GSK-3
AU2003278249B8 (en)	2002-09-05	2010-11-18	Aventis Pharma S.A.	Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
FR2844267B1 (fr) *	2002-09-05	2008-02-15	Aventis Pharma Sa	Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
WO2004030672A1 (en) *	2002-10-02	2004-04-15	Merck Patent Gmbh	Use of 4 amino-quinazolines as anti cancer agents
ES2440217T3 (es)	2002-10-04	2014-01-28	Prana Biotechnology Limited	Compuestos neurológicamente activos
KR100490893B1 (ko) *	2002-10-11	2005-05-23	(주) 비엔씨바이오팜	2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
GB0226583D0 (en) *	2002-11-14	2002-12-18	Cyclacel Ltd	Compounds
FR2847253B1 (fr) *	2002-11-19	2007-05-18	Aventis Pharma Sa	Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
US7462613B2 (en)	2002-11-19	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7309701B2 (en)	2002-11-19	2007-12-18	Sanofi-Aventis Deutschland Gmbh	Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
AU2003295776B2 (en) *	2002-11-21	2011-05-12	Novartis Vaccines And Diagnostics, Inc.	2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
WO2004072029A2 (en)	2003-02-06	2004-08-26	Vertex Pharmaceuticals Incorporated	Pyrazolopyridazines useful as inhibitors of protein kinases
US7157455B2 (en) *	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives
WO2004087679A1 (en) *	2003-04-01	2004-10-14	Aponetics Ag	2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
DE602004015108D1 (de) *	2003-06-02	2008-08-28	Astrazeneca Ab	(3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
ATE532781T1 (de) *	2003-06-19	2011-11-15	Glaxosmithkline Llc	5-(acylamino)indazol-derivate als kinase- inhibitoren
US8309562B2 (en)	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
US7618975B2 (en) *	2003-07-03	2009-11-17	Myriad Pharmaceuticals, Inc.	4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
TWI372050B (en) *	2003-07-03	2012-09-11	Astex Therapeutics Ltd	(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315966D0 (en) *	2003-07-08	2003-08-13	Cyclacel Ltd	Compounds
AU2004261459B2 (en)	2003-07-22	2008-06-26	Astex Therapeutics Limited	3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
EP1648875A1 (de) *	2003-07-30	2006-04-26	Cyclacel Limited	2-aminophenyl-4-phenylpyrimidine als kinaseinhibitoren
ES2421139T3 (es)	2003-07-30	2013-08-29	Rigel Pharmaceuticals, Inc.	Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
US20060024690A1 (en) *	2003-09-19	2006-02-02	Kao H P	Normalization of data using controls
US7417726B2 (en) *	2003-09-19	2008-08-26	Applied Biosystems Inc.	Normalization of data using controls
US20050221357A1 (en) *	2003-09-19	2005-10-06	Mark Shannon	Normalization of gene expression data
US20050124562A1 (en) *	2003-09-23	2005-06-09	Joseph Guiles	Bis-quinazoline compounds for the treatment of bacterial infections
ES2328820T3 (es)	2003-10-17	2009-11-18	Astrazeneca Ab	Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
US7592340B2 (en) *	2003-12-04	2009-09-22	Vertex Pharmaceuticals Incorporated	Quinoxalines useful as inhibitors of protein kinases
AU2004297241A1 (en) *	2003-12-09	2005-06-23	Vertex Pharmaceuticals Incorporated	Naphthyridine derivatives and their use as modulators of muscarinic receptors
EP1694686A1 (de) *	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinaseinhibitoren
TW200530235A (en)	2003-12-24	2005-09-16	Renovis Inc	Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
CA2556239A1 (en)	2004-02-11	2005-08-25	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
US20080050314A1 (en) *	2004-02-26	2008-02-28	Bayer Healthcare Ag	Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b)
CA2560111A1 (en) *	2004-03-15	2005-09-22	Takeda Pharmaceutical Company Limited	Aminophenylpropanoic acid derivative
WO2005099688A2 (en) *	2004-04-07	2005-10-27	Takeda Pharmaceutical Company Limited	Cyclic compounds
EP1742921A2 (de) *	2004-04-21	2007-01-17	AstraZeneca AB	Zur behandlung von krebs geeignete pyrazolderivate
WO2005105788A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Indole derivatives and use thereof as kinase inhibitors
WO2005113494A2 (en) *	2004-05-07	2005-12-01	Amgen Inc.	Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7793137B2 (en)	2004-10-07	2010-09-07	Cisco Technology, Inc.	Redundant power and data in a wired data telecommunincations network
AU2005243175B2 (en) *	2004-05-14	2011-12-01	Millennium Pharmaceuticals, Inc.	Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
NZ551583A (en) *	2004-05-14	2009-05-31	Vertex Pharma	Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors
SI1771450T1 (sl) *	2004-05-14	2008-06-30	Millennium Pharm Inc	Spojine in postopki za inhibiranje mitotične progresije z inhibicijo kinaze Aurora
AU2012200416B2 (en) *	2004-05-14	2014-07-31	Millennium Pharmaceuticals, Inc.	"Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
US20050255485A1 (en) *	2004-05-14	2005-11-17	Livak Kenneth J	Detection of gene duplications
US20080009531A1 (en) *	2004-05-20	2008-01-10	Bayer Pharmaceuticals Corporation	5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes
CN1973247A (zh) *	2004-05-27	2007-05-30	纳幕尔杜邦公司	光聚合物保护层的显影剂
CA2571178A1 (en) *	2004-07-01	2006-01-19	Synta Pharmaceuticals Corp.	2-substituted heteroaryl compounds
EP1768964A1 (de) *	2004-07-06	2007-04-04	Angion Biomedica Corporation	Chinazolinmodulatoren des hepatozytenwachstumsfaktors/der c-met-aktivität für die behandlung von krebs
WO2006023931A2 (en) *	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
TW200624431A (en)	2004-09-24	2006-07-16	Hoffmann La Roche	Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US7285569B2 (en)	2004-09-24	2007-10-23	Hoff Hoffmann-La Roche Inc.	Tricycles, their manufacture and use as pharmaceutical agents
ES2371924T3 (es) *	2004-09-30	2012-01-11	Tibotec Pharmaceuticals	Pirimidinas 5-carbo o heterociclo- sustituidas que inhiben el hiv.
ATE542802T1 (de) *	2004-09-30	2012-02-15	Tibotec Pharm Ltd	Hiv-inhibierende 5-substituierte pyrimidine
US8575342B2 (en) *	2004-09-30	2013-11-05	Tibotech Pharmaceuticals Ltd.	HIV inhibiting 5-heterocyclyl pyrimidines
EP1812439B2 (de)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinaseinhibitoren
NZ554441A (en) *	2004-10-29	2009-07-31	Banyu Pharma Co Ltd	Novel aminopyridine derivatives having aurora A selective inhibitory action
US7491720B2 (en) *	2004-10-29	2009-02-17	Banyu Pharmaceutical Co., Ltd.	Aminopyridine derivatives having Aurora A selective inhibitory action
JP2008519034A (ja)	2004-11-03	2008-06-05	バーテックスファーマシューティカルズインコーポレイテッド	イオンチャネル調節剤としてのピリミジン誘導体および使用方法
BRPI0517737A (pt) *	2004-11-17	2008-10-21	Miikana Therapeutics Inc	inibidores de quinase
ES2380550T3 (es)	2004-11-24	2012-05-16	Rigel Pharmaceuticals, Inc.	Compuestos de espiro-2,4-pirimidindiamina y sus usos
US20060128710A1 (en) *	2004-12-09	2006-06-15	Chih-Hung Lee	Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
EP1831216A2 (de) *	2004-12-23	2007-09-12	Pfizer Products Inc.	Als antikrebsmittel geeignete heteroaromatische derivate
WO2006070195A1 (en) *	2004-12-30	2006-07-06	Astex Therapeutics Limited	Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
AU2005322855B2 (en)	2004-12-30	2012-09-20	Exelixis, Inc.	Pyrimidine derivatives as kinase modulators and method of use
US8258145B2 (en)	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
EP1833482A4 (de)	2005-01-03	2011-02-16	Myriad Genetics Inc	Verbindungen und ihre therapeutische verwendung
AU2006206458B2 (en)	2005-01-19	2012-10-25	Rigel Pharmaceuticals, Inc.	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
CN101146796A (zh) *	2005-01-26	2008-03-19	先灵公司	作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
PT2383268E (pt)	2005-02-04	2015-12-21	Astrazeneca Ab	Derivados de pirazolilaminopiridina úteis como inibidores de quinase
DK1853588T3 (da) *	2005-02-16	2008-09-15	Astrazeneca Ab	Kemiske forbindelser
AU2006215394B2 (en) *	2005-02-16	2009-10-08	Astrazeneca Ab	Chemical compounds
MX2007011316A (es) *	2005-03-15	2007-11-12	Irm Llc	Compuestos y composiciones como inhibidores de cinasa de proteina.
US20080161278A1 (en) *	2005-03-23	2008-07-03	Astrazeneca Ab	2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity
US7297700B2 (en) *	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US20080167297A1 (en) *	2005-04-05	2008-07-10	Astrazeneca Ab	Pyrimidine Derivatives for Use as Anticancer Agents
GB0507347D0 (en) *	2005-04-12	2005-05-18	Astrazeneca Ab	Chemical compounds
AU2006233537A1 (en)	2005-04-14	2006-10-19	F. Hoffmann-La Roche Ag	Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
JP2008540335A (ja) *	2005-04-27	2008-11-20	アストラゼネカ・アクチエボラーグ	ピラゾリル・ピリミジン誘導体の疼痛治療における使用
JP5075624B2 (ja) *	2005-04-28	2012-11-21	田辺三菱製薬株式会社	シアノピリジン誘導体及びその医薬としての用途
WO2006119504A2 (en)	2005-05-04	2006-11-09	Renovis, Inc.	Fused heterocyclic compounds, and compositions and uses thereof
WO2006117212A2 (en)	2005-05-04	2006-11-09	Develogen Aktiengesellschaft	Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
JP2008540391A (ja) *	2005-05-05	2008-11-20	アストラゼネカアクチボラグ	ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
CA2608009A1 (en) *	2005-05-16	2006-11-23	Astrazeneca Ab	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
SG137989A1 (en)	2005-06-08	2008-01-28	Rigel Pharmaceuticals Inc	Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US8193206B2 (en)	2005-06-14	2012-06-05	Taigen Biotechnology Co., Ltd.	Pyrimidine compounds
EP1890703B1 (de)	2005-06-14	2016-05-11	Taigen Biotechnology	Pyrimidinverbindungen als chemokine rezeptoren inhibitoren
EP1746096A1 (de)	2005-07-15	2007-01-24	4Sc Ag	2-Arylbenzothiazol-Analoge zur Verwendung als Antikrebsmittel
ATE542814T1 (de) *	2005-08-18	2012-02-15	Vertex Pharma	Pyrazinkinaseinhibitoren
WO2007023382A2 (en) *	2005-08-25	2007-03-01	Pfizer Inc.	Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007025177A2 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258359A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
UA96427C2 (en) *	2005-09-30	2011-11-10	Мийкана Терапьютикс, Инк.	Substituted pyrazole compounds
NZ567241A (en) *	2005-09-30	2010-08-27	Miikana Therapeutics Inc	Substituted pyrazole compounds
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
ES2391783T3 (es)	2005-10-28	2012-11-29	Astrazeneca Ab	Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
EP1942879A1 (de)	2005-10-31	2008-07-16	Braincells, Inc.	Gaba-rezeptor-vermittelte modulation von neurogenese
EP1948652B1 (de) *	2005-11-01	2011-08-24	Array Biopharma, Inc.	Glucokinaseaktivatoren
JP5328361B2 (ja) *	2005-11-03	2013-10-30	バーテックスファーマシューティカルズインコーポレイテッド	キナーゼインヒビターとして有用なアミノピリミジン
JP2009515992A (ja) *	2005-11-16	2009-04-16	バーテックスファーマシューティカルズインコーポレイテッド	キナーゼ阻害剤として有用なアミノピリミジン
US8546404B2 (en)	2005-12-13	2013-10-01	Merck Sharp & Dohme	Compounds that are ERK inhibitors
US7572809B2 (en)	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
JP5474354B2 (ja)	2005-12-30	2014-04-16	アステックス、セラピューティックス、リミテッド	医薬化合物
WO2007081978A2 (en) *	2006-01-11	2007-07-19	Angion Biomedica Corporation	Modulators of hepatocyte growth factor / c-met activity
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
EP1984331B1 (de)	2006-02-16	2010-10-20	Schering Corporation	Pyrrolidin-derivate als erk-hemmer
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
PE20080145A1 (es)	2006-03-21	2008-02-11	Janssen Pharmaceutica Nv	Tetrahidro-pirimidoazepinas como moduladores de trpv1
ES2465666T3 (es) *	2006-03-30	2014-06-06	Janssen R&D Ireland	Pirimidinas 5-amido-sustituidas inhibidoras del HIV
EP2001480A4 (de) *	2006-03-31	2011-06-15	Abbott Lab	Indazol-verbindungen
ES2400375T3 (es)	2006-04-07	2013-04-09	Novartis Ag	Combinación que comprende A) un compuesto de pirimidilaminobenzamida y B)un inhibidor de cinasa THR315LLE
CN101534826A (zh)	2006-04-14	2009-09-16	普拉纳生物技术有限公司	治疗与年龄相关的黄斑变性（amd）的方法
AU2007244183B2 (en) *	2006-04-27	2012-05-10	Msd K.K.	Novel aminopyridine derivative having aurora-a-selective inhibitory activity
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
CA2838448A1 (en)	2006-06-27	2008-01-03	Takeda Pharmaceutical Company Limited	Fused cyclic compounds
WO2008001115A2 (en)	2006-06-29	2008-01-03	Astex Therapeutics Limited	Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
EP2043635A2 (de) *	2006-06-29	2009-04-08	Astex Therapeutics Limited	Pharmazeutische kombinationen
WO2008001886A1 (fr) *	2006-06-30	2008-01-03	Kyowa Hakko Kirin Co., Ltd.	Inhibiteur d'aurora
CA2654852A1 (en) *	2006-06-30	2008-01-03	Astrazeneca Ab	Pyrimidine derivatives useful in the treatment of cancer
EP2043651A2 (de)	2006-07-05	2009-04-08	Exelixis, Inc.	Verfahren zur verwendung von igf1r und abl-kinase-modulatoren
MX2009001043A (es)	2006-08-08	2009-02-06	Sanofi Aventis	Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
EP2054413A2 (de) *	2006-08-09	2009-05-06	Millennium Pharmaceuticals, Inc.	Pyridobenzazepin-verbindungen und verfahren zur hemmung von mitoseprogression
US7744164B2 (en) *	2006-08-11	2010-06-29	Schluimberger Technology Corporation	Shield of a degradation assembly
JP2008081492A (ja) *	2006-08-31	2008-04-10	Banyu Pharmaceut Co Ltd	オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
KR20090064418A (ko) *	2006-09-08	2009-06-18	브레인셀즈 인코퍼레이션	4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP2223925A1 (de) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Kinase-Inhibitoren
MX2009003793A (es)	2006-10-09	2009-12-14	Takeda Pharmaceutical	Inhibidores de cinasa.
JP5528807B2 (ja)	2006-10-12	2014-06-25	アステックス、セラピューティックス、リミテッド	複合薬剤
WO2008044041A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008053812A1 (fr) *	2006-10-27	2008-05-08	Mitsubishi Tanabe Pharma Corporation	Dérivé de cyanopyridine et son utilisation médicale
EP2086965B1 (de) *	2006-11-02	2010-02-10	Vertex Pharmaceuticals, Inc.	Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
CL2007003244A1 (es)	2006-11-16	2008-04-04	Millennium Pharm Inc	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
EP2099787B1 (de)	2006-12-19	2010-07-21	Vertex Pharmaceuticals, Inc.	Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2008080964A1 (en) *	2006-12-29	2008-07-10	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 6-substituted pyrimidines
WO2008080965A2 (en) *	2006-12-29	2008-07-10	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 5,6-substituted pyrimidines
ATE551334T1 (de)	2007-02-06	2012-04-15	Novartis Ag	Pi3-kinase-hemmer und verfahren zu ihrer verwendung
JPWO2008111441A1 (ja)	2007-03-05	2010-06-24	協和発酵キリン株式会社	医薬組成物
NZ579483A (en)	2007-03-09	2012-07-27	Vertex Pharma	Aminopyridines useful as inhibitors of protein kinases
CN101663295B (zh) *	2007-03-09	2014-11-05	沃泰克斯药物股份有限公司	可用作蛋白激酶抑制剂的氨基嘧啶类化合物
CN101668760B (zh) *	2007-03-09	2013-07-24	沃泰克斯药物股份有限公司	用作蛋白激酶抑制剂的氨基嘧啶类
CA2682195A1 (en) *	2007-03-20	2008-09-25	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
WO2008117050A1 (en) *	2007-03-27	2008-10-02	Astrazeneca Ab	Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
NZ580343A (en) *	2007-04-13	2012-03-30	Vertex Pharma	Aminopyrimidines useful as kinase inhibitors
DK2146779T3 (en)	2007-04-18	2016-11-28	Pfizer Prod Inc	Sulfonylamid derivatives to treat abnormal cell growth.
CN101679429A (zh) *	2007-04-18	2010-03-24	阿斯利康(瑞典)有限公司	5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
CN101801959A (zh) *	2007-05-02	2010-08-11	沃泰克斯药物股份有限公司	可用作激酶抑制剂的氨基嘧啶类化合物
WO2008137619A2 (en)	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
JP5572087B2 (ja) *	2007-05-02	2014-08-13	バーテックスファーマシューティカルズインコーポレイテッド	キナーゼ阻害として有用なアミノピリミジン
UA99459C2 (en)	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2010526048A (ja) *	2007-05-04	2010-07-29	アストラゼネカアクチボラグ	アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用
CA2687966A1 (en) *	2007-05-24	2008-12-04	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
KR101294731B1 (ko) *	2007-06-04	2013-08-16	삼성디스플레이 주식회사	어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
EP2166849A4 (de) *	2007-06-11	2010-09-15	Miikana Therapeutics Inc	Substituierte pyrazol-verbindungen
WO2009008992A2 (en) *	2007-07-06	2009-01-15	Osi Pharmaceuticals Inc.	Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
WO2009007753A2 (en) *	2007-07-11	2009-01-15	Astrazeneca Ab	4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
WO2009015254A1 (en) *	2007-07-25	2009-01-29	Bristol-Myers Squibb Company	Triazine kinase inhibitors
WO2009013545A2 (en) *	2007-07-26	2009-01-29	Astrazeneca Ab	Chemical compounds
CA2694499A1 (en)	2007-07-31	2009-02-05	Vertex Pharmaceuticals Incorporated	Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
TW200906818A (en) *	2007-07-31	2009-02-16	Astrazeneca Ab	Chemical compounds
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009027736A2 (en) *	2007-08-27	2009-03-05	Astrazeneca Ab	2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
KR101566042B1 (ko)	2007-09-21	2015-11-04	어레이 바이오파마 인크.	진성 당뇨병을 치료하기 위한 글루코키나제 활성화제로서의 피리딘-２-일-아미노-１,２,４-티아디아졸 유도체
SI2214487T1 (sl)	2007-10-11	2014-03-31	Glaxosmithkline Llc	Novi sEH inhibitorji in njihova uporaba
US8288397B2 (en)	2007-12-17	2012-10-16	Janssen Pharmaceutica Nv	Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
US20090270418A1 (en) *	2008-01-09	2009-10-29	Marianne Sloss	Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2242745A1 (de) *	2008-02-07	2010-10-27	Sanofi-Aventis	Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
BRPI0908120A8 (pt) *	2008-02-21	2017-10-24	Schering Corp	Compostos que são inibidores de erk, composição faramacêutica e uso
EP2254888B1 (de) *	2008-02-22	2014-12-24	Msd K.K.	Neue aminopyridinderivate mit einer selektivaurora-a-hemmenden wirkung
HUE025179T2 (en)	2008-04-21	2016-02-29	Taigen Biotechnology Co Ltd	Heterocyclic Compounds
WO2010011411A1 (en)	2008-05-27	2010-01-28	The Trustees Of Columbia University In The City Of New York	Systems, methods, and media for detecting network anomalies
MX2010013682A (es) *	2008-06-11	2011-03-15	Astrazeneca Ab	Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
TW201014822A (en)	2008-07-09	2010-04-16	Sanofi Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
BRPI0911688A2 (pt) *	2008-07-31	2015-07-28	Genentech Inc	"compostos de pirimidina, composições e métodos de uso"
RU2011112802A (ru) *	2008-09-03	2012-10-10	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Сокристаллы и содержащие их фармацевтические композиции
WO2010028236A1 (en) *	2008-09-05	2010-03-11	Avila Therapeutics, Inc.	Algorithm for designing irreversible inhibitors
WO2010031056A2 (en)	2008-09-15	2010-03-18	The Regents Of The University Of California	Methods and compositions for modulating ire1, src, and abl activity
US20110201628A1 (en) *	2008-09-30	2011-08-18	Astrazeneca Ab	Heterocyclic jak kinase inhibitors
US8759362B2 (en) *	2008-10-24	2014-06-24	Purdue Pharma L.P.	Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010056758A1 (en) *	2008-11-12	2010-05-20	Yangbo Feng	Quinazoline derivatives as kinase inhibitors
WO2010056847A2 (en)	2008-11-13	2010-05-20	Taigen Biotechnology Co., Ltd.	Lyophilization formulation
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PA8851101A1 (es)	2008-12-16	2010-07-27	Lilly Co Eli	Compuesto amino pirazol
EP2373664B1 (de)	2008-12-19	2013-06-12	Nerviano Medical Sciences S.r.l.	Bicyclische pyrazole als proteinkinaseinhibitoren
CA2747326C (en)	2008-12-22	2017-05-16	Millennium Pharmaceuticals, Inc.	Combination of aurora kinase inhibitors and anti-cd20 antibodies
US8809343B2 (en)	2008-12-26	2014-08-19	Fudan University	Pyrimidine derivative, preparation method and use thereof
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
TWI476192B (zh) *	2009-02-27	2015-03-11	Ambit Biosciences Corp	Ｊａｋ激酶調節化合物及其使用方法
CA2660962A1 (en)	2009-03-31	2010-09-30	Astellas Pharma Inc.	Novel pharmaceutical composition for treatment of schizophrenia
US8399663B2 (en)	2009-04-03	2013-03-19	Astellas Pharma Inc.	Salt of 1,3,5-triazine-2,4,6-triamine derivative
JO3635B1 (ar)	2009-05-18	2020-08-27	Millennium Pharm Inc	مركبات صيدلانية صلبة وطرق لانتاجها
EP2440052A4 (de) *	2009-06-08	2013-01-23	Abraxis Bioscience Llc	Triazinderivate und deren therapeutische anwendungen
CA2764785C (en) *	2009-06-08	2015-10-27	California Capital Equity, Llc	Triazine derivatives and their therapeutical applications
KR20120026612A (ko)	2009-06-09	2012-03-19	아브락시스 바이오사이언스, 엘엘씨	벤질 치환 트리아진 유도체와 이들의 치료적 용도
US20120202818A1 (en) *	2009-06-09	2012-08-09	California Capital Equity, Llc	Ureidophenyl substituted triazine derivatives and their therapeutical applications
CA2765030C (en)	2009-06-09	2015-10-27	California Capital Equity, Llc	Triazine derivatives and their therapeutical applications
WO2010144423A1 (en) *	2009-06-09	2010-12-16	Abraxis Bioscience, Llc	Styryl-triazine derivatives and their therapeutical applications
US20120172384A1 (en) *	2009-06-18	2012-07-05	Mihiro Sunose	Heterocyclylaminopyrimidines as kinase inhibitors
TWI468402B (zh) *	2009-07-31	2015-01-11	必治妥美雅史谷比公司	降低β－類澱粉生成之化合物
US8637525B2 (en)	2009-07-31	2014-01-28	Bristol-Myers Squibb Company	Compounds for the reduction of beta-amyloid production
BR112012003973A2 (pt)	2009-08-26	2015-09-08	Sanofi Sa	hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
CN102713618B (zh)	2009-09-16	2015-07-15	新基阿维罗米克斯研究公司	蛋白激酶复合物和抑制剂
KR102009224B1 (ko) *	2009-11-13	2019-08-09	인튜어티브 서지컬 오퍼레이션즈 인코포레이티드	여분의 닫힘 메커니즘을 구비한 단부 작동기
CA2784807C (en)	2009-12-29	2021-12-14	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
RU2012132473A (ru)	2009-12-30	2014-02-10	Селджин Авиломикс,Инк	Лиганд-направленная ковалентная модификация белка
SA111320200B1 (ar) *	2010-02-17	2014-02-16	ديبيوفارم اس ايه	مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
CN104031049A (zh)	2010-02-19	2014-09-10	米伦纽姆医药公司	极光激酶抑制剂的结晶形式
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2571359A4 (de) *	2010-05-20	2013-10-23	Merck Sharp & Dohme	Neuartige prolylcarboxypeptidase-hemmer
RU2528386C2 (ru)	2010-05-21	2014-09-20	Кемилиа Аб	Новые производные пиримидина
KR101531448B1 (ko)	2010-06-04	2015-06-24	에프. 호프만-라 로슈 아게	Lrrk2 조절제로서의 아미노피리미딘 유도체
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP6054868B2 (ja)	2010-07-29	2016-12-27	オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎＧｅｎｏｍｉｃｓＳ．Ａ．	Ｌｓｄ１のアリールシクロプロピルアミンをベースとしたデメチラーゼ阻害剤およびそれらの医学的使用
EP2611502A1 (de) *	2010-09-01	2013-07-10	Ambit Biosciences Corporation	Adenosin-a3-rezeptormodulierende verbindungen und ihre verwendung
US20130225614A1 (en) *	2010-09-01	2013-08-29	Ambit Biosciences Corporation	4-azolylaminoquinazoline derivatives and methods of use thereof
AU2011296078B2 (en) *	2010-09-01	2015-06-18	Ambit Biosciences Corporation	An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
JP5872558B2 (ja) *	2010-09-01	2016-03-01	アムビトビオスシエンセスコルポラチオン	ピラゾリルアミノキナゾリンの臭化水素酸塩
WO2012030944A2 (en) *	2010-09-01	2012-03-08	Ambit Biosciences Corporation	Quinoline and isoquinoline compounds and methods of use thereof
US8633207B2 (en)	2010-09-01	2014-01-21	Ambit Biosciences Corporation	Quinazoline compounds and methods of use thereof
US20130225615A1 (en) *	2010-09-01	2013-08-29	Ambit Biosciences Corporation	2-cycloquinazoline derivatives and methods of use thereof
WO2012059932A1 (en)	2010-11-01	2012-05-10	Aurigene Discovery Technologies Limited	2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
PT3124483T (pt)	2010-11-10	2019-10-02	Genentech Inc	Derivados de pirazol aminopirimidina como moduladores de lrrk2
US8895547B2 (en)	2011-03-08	2014-11-25	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en)	2011-03-08	2014-12-02	Sanofi	Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683698B1 (de)	2011-03-08	2017-10-04	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2012230229A1 (en)	2011-03-24	2013-10-10	Noviga Research Ab	Novel pyrimidine derivatives
BR112014003997A2 (pt) *	2011-08-25	2017-03-21	Hoffmann La Roche	composto, método para inibição da atividade de pak1 em uma célula e paciente, método para o tratamento ou melhoria da gravidade do câncer ou de um distúrbio hiperproliferativo em um paciente, utilização do composto e composição
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX2014003501A (es) *	2011-09-22	2014-07-22	Pfizer	Derivados de pirrolopirimidina y purina.
AP3907A (en)	2011-09-27	2016-11-23	Novartis Ag	3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
EP2760862B1 (de)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
EP3569598A1 (de)	2011-11-17	2019-11-20	Dana Farber Cancer Institute, Inc.	Inhibitoren der c-jun-n-terminal-kinase (jnk)
EP2794605A1 (de)	2011-12-22	2014-10-29	F.Hoffmann-La Roche Ag	2,4-diaminpyrimidinderivat als serin-/threoninkinasehemmer
RU2014137448A (ru) *	2012-02-17	2016-04-10	Эббви Инк.	Диаминопиримидины, пригодные в качестве ингибиторов респираторно-синцитиального вируса человека (rsv)
UY34632A (es)	2012-02-24	2013-05-31	Novartis Ag	Compuestos de oxazolidin- 2- ona y usos de los mismos
TWI485146B (zh) *	2012-02-29	2015-05-21	Taiho Pharmaceutical Co Ltd	Novel piperidine compounds or salts thereof
CA2867467A1 (en)	2012-03-16	2013-09-19	Axikin Pharmaceuticals, Inc.	3,5-diaminopyrazole kinase inhibitors
US20130303519A1 (en)	2012-03-20	2013-11-14	Millennium Pharmaceuticals, Inc.	Methods of treating cancer using aurora kinase inhibitors
IN2014KN02601A (de)	2012-04-24	2015-05-08	Vertex Pharma
JP6197031B2 (ja) *	2012-05-24	2017-09-13	セルゾームリミティッド	Ｔｙｋ２阻害剤としてのヘテロシクリルピリミジン類似体
MX367055B (es)	2012-06-26	2019-08-02	Del Mar Pharmaceuticals	El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
ES2589558T3 (es) *	2012-07-10	2016-11-15	Ares Trading S.A.	Derivados de pirimidin pirazolilo
PL2898886T3 (pl) *	2012-09-19	2017-06-30	Taiho Pharmaceutical Co., Ltd.	Kompozycja farmaceutyczna do podawania doustnego z polepszoną elucją i/lub wchłanianiem
US9296733B2 (en)	2012-11-12	2016-03-29	Novartis Ag	Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103202843B (zh) *	2012-12-31	2015-04-29	刘强	一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
CN103191120B (zh) *	2012-12-31	2015-11-25	刘强	一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗肿瘤的药物中的用途
CN103059002B (zh) *	2012-12-31	2015-04-22	中山大学	具有Aurora激酶抑制活性的嘧啶衍生物及其制备方法以及应用
CN103910716A (zh) *	2013-01-07	2014-07-09	华东理工大学	2,4-二取代-环烷基[d]嘧啶类化合物及其用途
PT2970218T (pt)	2013-03-12	2019-03-01	Vertex Pharma	Inibidores de adn-pk
CA2903979A1 (en)	2013-03-14	2014-09-18	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP3842424B1 (de)	2013-03-15	2024-12-11	The Trustees of Columbia University in the City of New York	Map-kinasemodulatoren und verwendungen davon zur behandlung von tauopathien
CA2907726A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015003355A2 (en) *	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
EP3024456A4 (de)	2013-07-26	2017-04-12	Update Pharma Inc.	Kombinatorische verfahren zur verbesserung des therapeutischen nutzens von bisantren
WO2015028848A1 (en) *	2013-09-02	2015-03-05	Piramal Enterprises Limited	Bicyclic heterocyclic compounds as multi-kinase inhibitors
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
ES2802296T3 (es)	2013-10-17	2021-01-18	Vertex Pharma	Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
CN105849099B (zh)	2013-10-18	2020-01-17	达纳-法伯癌症研究所股份有限公司	周期蛋白依赖性激酶7(cdk7)的多环抑制剂
WO2015058126A1 (en)	2013-10-18	2015-04-23	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
US10030004B2 (en)	2014-01-01	2018-07-24	Medivation Technologies Llc	Compounds and methods of use
HUE052642T2 (hu)	2014-03-13	2021-05-28	Neuroderm Ltd	DOPA dekarboxiláz inhibitor készítmények
US10258585B2 (en)	2014-03-13	2019-04-16	Neuroderm, Ltd.	DOPA decarboxylase inhibitor compositions
MX2016012574A (es) *	2014-03-28	2017-09-26	Calitor Sciences Llc	Compuestos heteroarilo sustituidos y metodos de uso.
EP3125883B1 (de)	2014-04-04	2020-08-12	Iomet Pharma Ltd.	Indolderivate zur verwendung in der medizin
WO2015155738A2 (en)	2014-04-09	2015-10-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN105367555B (zh) *	2014-08-07	2019-06-25	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
JP6854762B2 (ja)	2014-12-23	2021-04-07	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
JP6450010B2 (ja)	2014-12-23	2019-01-09	アクシキンファーマシューティカルズインコーポレーテッド	３，５−ジアミノピラゾールキナーゼ阻害剤
US10227343B2 (en) *	2015-01-30	2019-03-12	Vanderbilt University	Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10550121B2 (en)	2015-03-27	2020-02-04	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
EP3283482B1 (de)	2015-04-17	2022-04-06	Ludwig Institute for Cancer Research Ltd	Plk4 hemmer
EP3303348B1 (de)	2015-05-28	2019-08-07	Theravance Biopharma R&D IP, LLC	Naphthyridin- verbindungen als jak kinase inhibitoren
JP2018135268A (ja) *	2015-06-05	2018-08-30	大日本住友製薬株式会社	新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
EP3324976A4 (de)	2015-07-21	2019-03-27	Millennium Pharmaceuticals, Inc.	Verabreichung eines aurora-kinase-inhibitors und chemotherapeutika
WO2017044858A2 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
US9938257B2 (en)	2015-09-11	2018-04-10	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
SI3386511T1 (sl) *	2015-12-10	2021-09-30	Ptc Therapeutics, Inc.	Postopki za zdravljenje Huntingtonove bolezni
CN105503754B (zh) *	2015-12-11	2017-11-17	浙江大学	2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
CN105399695B (zh) *	2015-12-11	2019-04-19	浙江大学	三嗪类化合物及其制备方法和用途
CN105384702B (zh) *	2015-12-11	2018-04-10	浙江大学	三取代均三嗪类化合物及其制备方法
WO2017102091A1 (en)	2015-12-18	2017-06-22	Bayer Pharma Aktiengesellschaft	Heteroarylbenzimidazole compounds
MX2018011136A (es)	2016-03-14	2019-01-14	Afferent Pharmaceuticals Inc	Pirimidinas y variantes de estas, y usos de estas.
MA44489A (fr)	2016-03-25	2019-01-30	Afferent Pharmaceuticals Inc	Pyrimidines et variants de celles-ci, et leurs utilisations
ES2779880T3 (es)	2016-04-28	2020-08-20	Theravance Biopharma R&D Ip Llc	Compuestos de pirimidina como inhibidores de la cinasa JAK
WO2017207534A1 (en)	2016-06-03	2017-12-07	Bayer Pharma Aktiengesellschaft	Substituted heteroarylbenzimidazole compounds
JP2019529475A (ja)	2016-09-27	2019-10-17	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
US10858319B2 (en)	2016-10-03	2020-12-08	Iomet Pharma Ltd.	Indole derivatives for use in medicine
WO2018089546A1 (en) *	2016-11-08	2018-05-17	Vanderbilt University	Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN108239071B (zh) *	2016-12-27	2020-12-04	沈阳药科大学	酰胺及硫代酰胺类衍生物及其制备方法和应用
FR3064275B1 (fr)	2017-03-21	2019-06-07	Arkema France	Procede de chauffage et/ou climatisation d'un vehicule
IL270873B2 (en)	2017-05-30	2023-04-01	Basf Se	"The history of pyridine and pyrazine compounds, a preparation containing them and their use as fungicides
CA3066224A1 (en)	2017-06-05	2018-12-13	Ptc Therapeutics Inc.	Compounds for treating huntington's disease
EP3645121A4 (de)	2017-06-28	2021-03-17	PTC Therapeutics, Inc.	Verfahren zur behandlung von morbus huntington
MX2019015578A (es)	2017-06-28	2020-07-28	Ptc Therapeutics Inc	Metodos para tratar la enfermedad de huntington.
US11390609B2 (en)	2017-06-30	2022-07-19	Beijing Tide Pharmaceutical Co., Ltd.	Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
JP2020525525A (ja) *	2017-06-30	2020-08-27	ベイジンタイドファーマシューティカルカンパニーリミテッドＢｅｉｊｉｎｇＴｉｄｅＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
JP7039802B2 (ja)	2017-06-30	2022-03-23	ベイジンタイドファーマシューティカルカンパニーリミテッド	Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
WO2019046163A1 (en) *	2017-08-28	2019-03-07	Zhihong Chen	SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND ASSOCIATED THERAPEUTIC METHODS
WO2019046316A1 (en) *	2017-08-28	2019-03-07	Acurastem Inc.	PIKFYVE KINASE INHIBITORS
BR112020008015A2 (pt)	2017-10-27	2020-10-27	Theravance Biopharma R&D Ip, Llc	composto derivado da pirimidina como inibidor da quinase jak
MX2020004536A (es) *	2017-11-23	2020-08-03	Biomed X Gmbh	Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).
US11612604B2 (en)	2017-12-06	2023-03-28	Ludwig Institute For Cancer Research Ltd	Methods of treating cancer with PLK4 inhibitors
BR112020019373A2 (pt)	2018-03-27	2020-12-29	Ptc Therapeutics, Inc.	Compostos para o tratamento da doença de hutington
EP3810132A4 (de) *	2018-06-25	2022-06-22	Dana-Farber Cancer Institute, Inc.	Kinaseinhibitoren der taire und ihre verwendungen
SI3814357T1 (sl)	2018-06-27	2024-09-30	Ptc Therapeutics, Inc.	Heterociklične in heteroarilne spojine za zdravljenje Huntingtonove bolezni
US11685746B2 (en)	2018-06-27	2023-06-27	Ptc Therapeutics, Inc.	Heteroaryl compounds for treating Huntington's disease
SG11202012869SA (en)	2018-06-27	2021-01-28	Ptc Therapeutics Inc	Heteroaryl compounds for treating huntington's disease
BR112021010358A2 (pt) *	2018-11-30	2021-08-24	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Derivados heteroaromáticos para uso como regulador, método para preparar os mesmos e uso dos mesmos
HRP20241053T1 (hr)	2019-04-24	2024-11-08	Theravance Biopharma R&D Ip, Llc	Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti
WO2020219639A1 (en)	2019-04-24	2020-10-29	Theravance Biopharma R&D Ip, Llc	Ester and carbonate pyrimidine compounds as jak kinase inhibitors
CN114728949B (zh) *	2019-08-01	2024-11-12	曙方医药	作为激酶抑制剂的杂环化合物及其用途
FI4031547T3 (fi)	2019-09-18	2024-09-16	Takeda Pharmaceuticals Co	Plasman kallikreiinin estäjiä ja niiden käyttötapoja
US11370803B2 (en)	2019-09-18	2022-06-28	Takeda Pharmaceutical Company Limited	Heteroaryl plasma kallikrein inhibitors
CN110483493A (zh) *	2019-09-19	2019-11-22	广东工业大学	一种二唑类衍生物及其制备方法和应用
US11844754B2 (en)	2020-11-17	2023-12-19	Neuroderm, Ltd.	Methods for treatment of Parkinson's disease
US11213502B1 (en)	2020-11-17	2022-01-04	Neuroderm, Ltd.	Method for treatment of parkinson's disease
US11331293B1 (en)	2020-11-17	2022-05-17	Neuroderm, Ltd.	Method for treatment of Parkinson's disease
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
US20240199613A1 (en) *	2021-03-17	2024-06-20	Takeda Pharmaceutical Company Limited	Polycyclic inhibitors of plasma kallikrein
CA3213359A1 (en) *	2021-03-26	2022-09-29	Bettina FRANZ	Alk-5 inhibitors and uses thereof
JP2024521657A (ja)	2021-05-11	2024-06-04	オリックファーマシューティカルズ，インク．	ポロ様キナーゼ４阻害剤
JP2024524373A (ja)	2021-06-28	2024-07-05	ブループリントメディシンズコーポレイション	Ｃｄｋ２阻害剤
KR102692529B1 (ko) *	2021-07-01	2024-08-08	한국원자력의학원	Mastl-pp2a를 표적화하는 암의 예방 또는 치료용 약학적 조성물
CN116354938B (zh) *	2021-12-28	2024-02-20	沈阳药科大学	一类喹唑啉衍生物与其类似物的制备方法及应用
CN114276302B (zh) *	2022-01-11	2023-07-25	山东百启生物医药有限公司	一种制备2,4-二氨基喹唑啉衍生物的方法
WO2024003773A1 (en)	2022-07-01	2024-01-04	Pfizer Inc.	2,7-naphthyridine compounds as mastl inhibitors
CN117736198A (zh) *	2022-09-21	2024-03-22	科辉智药生物科技(深圳)有限公司	大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
CN115403568B (zh) *	2022-09-21	2023-09-29	中山大学	一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用
US20240317777A1 (en) *	2023-02-23	2024-09-26	Accutar Biotechnology Inc.	Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors
US12161612B2 (en)	2023-04-14	2024-12-10	Neuroderm, Ltd.	Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2585906A (en)		1952-02-12		Quaternary salts of pyrimdjines
US3133081A (en)		1964-05-12		J-aminoindazole derivatives
US18436A (en) *		1857-10-20		And saml
US3935183A (en)	1970-01-26	1976-01-27	Imperial Chemical Industries Limited	Indazole-azo phenyl compounds
BE754242A (fr)	1970-07-15	1971-02-01	Geigy Ag J R	Diamino-s-triazines et dinitro-s-triazines
US3755332A (en) *	1971-07-01	1973-08-28	Ciba Geigy Corp	Substituted 4 indazolaminoquinolines
US3998951A (en) *	1974-03-13	1976-12-21	Fmc Corporation	Substituted 2-arylquinazolines as fungicides
DE2458965C3 (de)	1974-12-13	1979-10-11	Bayer Ag, 5090 Leverkusen	3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
MA18829A1 (fr)	1979-05-18	1980-12-31	Ciba Geigy Ag	Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DOP1981004033A (es) *	1980-12-23	1990-12-29	Ciba Geigy Ag	Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
SE8102194L (sv)	1981-04-06	1982-10-07	Pharmacia Ab	Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
SE8102193L (sv)	1981-04-06	1982-10-07	Pharmacia Ab	Terapeutiskt aktiv organisk forening och dess anvendning
JPS58124773A (ja)	1982-01-20	1983-07-25	Mitsui Toatsu Chem Inc	５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤
EP0136976A3 (de)	1983-08-23	1985-05-15	Ciba-Geigy Ag	Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
DE3725638A1 (de)	1987-08-03	1989-02-16	Bayer Ag	Neue aryloxy (bzw. thio)aminopyrimidine
JPH0532662A (ja)	1990-11-09	1993-02-09	Nissan Chem Ind Ltd	置換ピラゾール誘導体および農園芸用殺菌剤
US5714493A (en) *	1991-05-10	1998-02-03	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5597920A (en)	1992-04-30	1997-01-28	Neurogen Corporation	Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JPH0665237A (ja) *	1992-05-07	1994-03-08	Nissan Chem Ind Ltd	置換ピラゾール誘導体および農園芸用殺菌剤
WO1995009851A1 (en)	1993-10-01	1995-04-13	Ciba-Geigy Ag	Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
CA2203517A1 (en)	1994-11-10	1996-05-23	Alan M. Laibelman	Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
IL117659A (en)	1995-04-13	2000-12-06	Dainippon Pharmaceutical Co	Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US5935966A (en)	1995-09-01	1999-08-10	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO1997009325A1 (en)	1995-09-01	1997-03-13	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
US6716575B2 (en)	1995-12-18	2004-04-06	Sugen, Inc.	Diagnosis and treatment of AUR1 and/or AUR2 related disorders
AU3766897A (en)	1996-07-13	1998-02-09	Glaxo Group Limited	Fused heterocyclic compounds as protein tyrosine kinase inhibitors
JPH10130150A (ja)	1996-09-05	1998-05-19	Dainippon Pharmaceut Co Ltd	酢酸アミド誘導体からなる医薬
GB9619284D0 (en)	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
CA2266519C (en)	1996-10-02	2007-01-23	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
EP0932598A1 (de)	1996-10-11	1999-08-04	Warner-Lambert Company	Asparat ester als inhibitoren von interleukin-1 beta-konvertierenden enzymen
BR9814817A (pt)	1997-10-10	2002-01-08	Cytovia Inc	Inibidores de apoptose de dipeptìdio e o uso dos mesmos
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
JP2000026421A (ja)	1998-01-29	2000-01-25	Kumiai Chem Ind Co Ltd	ジアリ―ルスルフィド誘導体及び有害生物防除剤
NZ506417A (en)	1998-02-17	2003-05-30	Tularik Inc	Anti-viral pyrimidine derivatives
DE69925268T2 (de)	1998-03-16	2006-03-23	Cytovia, Inc., San Diego	Dipeptid-Caspase-Inhibitoren und deren Verwendung
IL139787A0 (en)	1998-06-02	2002-02-10	Osi Pharm Inc	PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
CN1312807A (zh)	1998-06-19	2001-09-12	希龙公司	糖元合成酶激酶3的抑制剂
WO2000003901A1 (de) *	1998-07-16	2000-01-27	Continental Teves Ag & Co. Ohg	Verfahren und vorrichtung zum ermitteln von kritischen fahrzuständen bei im fahrbetrieb befindlichen fahrzeugen
WO2000011003A1 (en)	1998-08-21	2000-03-02	Du Pont Pharmaceuticals Company	ISOXAZOLO[4,5-d]PYRIMIDINES AS CRF ANTAGONISTS
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
ATE294796T1 (de) *	1998-10-08	2005-05-15	Astrazeneca Ab	Chinazolin derivate
GB9828640D0 (en)	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
TR200102029T2 (tr)	1999-01-13	2001-11-21	Warner-Lambert Company	1-Heterosiklil ikameli diarilaminler.
AU766081B2 (en)	1999-03-30	2003-10-09	Novartis Ag	Phthalazine derivatives for treating inflammatory diseases
AU781849C (en) *	1999-06-17	2006-03-02	Synta Pharmaceuticals Corp.	Inhibitors of IL-12 production
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
ATE402163T1 (de)	1999-08-13	2008-08-15	Vertex Pharma	Inhibitoren der c-jun n-terminalen kinase (jnk) und andere protein-kinasen
DE60039059D1 (de) *	1999-10-07	2008-07-10	Amgen Inc	Triazin-kinase-hemmer
CN1402720A (zh)	1999-11-30	2003-03-12	辉瑞产品公司	用作免疫抑制剂的2,4－二氨基嘧啶化合物
JP2003519102A (ja)	1999-12-02	2003-06-17	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	アデノシンａ▲下１▼、ａ▲下２ａ▼およびａ▲下３▼受容体に対して特異的な化合物並びにその使用
MY125768A (en)	1999-12-15	2006-08-30	Bristol Myers Squibb Co	N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6376489B1 (en)	1999-12-23	2002-04-23	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
SK14082001A3 (sk)	2000-02-05	2002-03-05	Vertex Pharmaceuticals Incorporated	Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje
MXPA02007957A (es) *	2000-02-17	2002-11-29	Amgen Inc	Inhibidores de cinasas.
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
JP4806154B2 (ja)	2000-04-03	2011-11-02	バーテックスファーマシューティカルズインコーポレイテッド	セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
CA2398446A1 (en)	2000-04-18	2001-10-25	Agouron Pharmaceuticals, Inc.	Pyrazoles for inhibiting protein kinases
JP3890184B2 (ja) *	2000-05-15	2007-03-07	Ｎｅｃパーソナルプロダクツ株式会社	電源装置及びその電力制御方法、情報処理機器
EE200200715A (et)	2000-06-28	2004-08-16	Astrazeneca Ab	Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
AP2001002266A0 (en)	2000-08-31	2001-09-30	Pfizer Prod Inc	Pyrazole derivatives.
US6613776B2 (en)	2000-09-15	2003-09-02	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en)	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
KR100896664B1 (ko)	2000-09-15	2009-05-14	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피라졸 화합물
US7473691B2 (en)	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en)	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6495582B1 (en)	2000-09-15	2002-12-17	Vertex Pharmaceuticals Incorporated	Isoxazole compositions useful as inhibitors of ERK
AU2001293817A1 (en)	2000-09-20	2002-04-02	Merck Patent Gmbh	4-amino-quinazolines
US6641579B1 (en)	2000-09-29	2003-11-04	Spectrasonics Imaging, Inc.	Apparatus and method for ablating cardiac tissue
DE10061863A1 (de)	2000-12-12	2002-06-13	Basf Ag	Verfahren zur Herstellung von Triethylendiamin (TEDA)
US6716851B2 (en)	2000-12-12	2004-04-06	Cytovia, Inc.	Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (de)	2000-12-12	2005-06-22	Cytovia Inc	Substituierte 2-aryl-4-arylaminopyrimidine und ihre analoge als aktivatoren von caspasen und apoptoseinduktoren, sowie deren verwendung
ATE326462T1 (de)	2000-12-21	2006-06-15	Vertex Pharma	Pyrazolverbindungen als protein-kinase- inhibitoren
MY130778A (en)	2001-02-09	2007-07-31	Vertex Pharma	Heterocyclic inhibitiors of erk2 and uses thereof
US6949544B2 (en)	2001-03-29	2005-09-27	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
WO2002083667A2 (en)	2001-04-13	2002-10-24	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AU2002305205A1 (en)	2001-04-20	2002-11-05	Jingrong Cao	9-deazaguanine derivatives as inhibitors of gsk-3
JP4316893B2 (ja)	2001-05-16	2009-08-19	バーテックスファーマシューティカルズインコーポレイテッド	Ｓｒｃおよび他のプロテインキナーゼのインヒビター
JP4541695B2 (ja)	2001-06-15	2010-09-08	バーテックスファーマシューティカルズインコーポレイテッド	プロテインキナーゼインヒビターとしての５−（２−アミノピリミジン−４−イル）ベンズイソキサゾール
WO2003004492A1 (en)	2001-07-03	2003-01-16	Vertex Pharmaceuticals Incorporated	Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
WO2003026664A1 (en) *	2001-09-26	2003-04-03	Bayer Corporation	2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US6569499B2 (en)	2001-10-02	2003-05-27	Xerox Corporation	Apparatus and method for coating photoreceptor substrates
AU2002364536B2 (en)	2001-12-07	2008-10-23	Vertex Pharmaceuticals, Inc.	Pyrimidine-based compounds useful as GSK-3 inhibitors
DE60327999D1 (de)	2002-03-15	2009-07-30	Vertex Pharma	Azolylaminoazine als inhibitoren von proteinkinasen
EP1485380B1 (de)	2002-03-15	2010-05-19	Vertex Pharmaceuticals Incorporated	Azolylaminoazine als proteinkinasehemmer
EP1485100B1 (de)	2002-03-15	2010-05-05	Vertex Pharmaceuticals Incorporated	Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de)	2002-03-15	2007-07-15	Vertex Pharma	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
US20030207873A1 (en)	2002-04-10	2003-11-06	Edmund Harrington	Inhibitors of Src and other protein kinases
WO2003091246A1 (en)	2002-04-26	2003-11-06	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
WO2004005283A1 (en)	2002-07-09	2004-01-15	Vertex Pharmaceuticals Incorporated	Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
CA2494100C (en)	2002-08-02	2011-10-11	Vertex Pharmaceuticals Incorporated	Pyrazole compositions useful as inhibitors of gsk-3
EP2099787B1 (de)	2006-12-19	2010-07-21	Vertex Pharmaceuticals, Inc.	Als inhibitoren von proteinkinasen geeignete aminopyrimidine

2001
- 2001-12-19 AT AT01994510T patent/ATE326462T1/de active
- 2001-12-19 PL PL363244A patent/PL210414B1/pl not_active IP Right Cessation
- 2001-12-19 PT PT01273861T patent/PT1355905E/pt unknown
- 2001-12-19 WO PCT/US2001/051120 patent/WO2002059111A2/en active IP Right Grant
- 2001-12-19 ES ES01994323T patent/ES2272567T3/es not_active Expired - Lifetime
- 2001-12-19 SI SI200130656T patent/SI1353916T1/sl unknown
- 2001-12-19 NZ NZ526468A patent/NZ526468A/en not_active IP Right Cessation
- 2001-12-19 DE DE60119774T patent/DE60119774T2/de not_active Expired - Lifetime
- 2001-12-19 PL PL363246A patent/PL210066B1/pl unknown
- 2001-12-19 AU AU2002255452A patent/AU2002255452B2/en not_active Ceased
- 2001-12-19 CN CNB01822136XA patent/CN100340555C/zh not_active Expired - Fee Related
- 2001-12-19 US US10/025,164 patent/US6664247B2/en not_active Expired - Fee Related
- 2001-12-19 CN CN2011101042845A patent/CN102250071A/zh active Pending
- 2001-12-19 JP JP2002559413A patent/JP4160392B2/ja not_active Expired - Fee Related
- 2001-12-19 ES ES01273861T patent/ES2280313T3/es not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/049140 patent/WO2002050065A2/en active IP Right Grant
- 2001-12-19 DE DE60120219T patent/DE60120219T2/de not_active Expired - Lifetime
- 2001-12-19 EP EP01985059A patent/EP1345925B1/de not_active Expired - Lifetime
- 2001-12-19 CN CNB018221351A patent/CN100408573C/zh not_active Expired - Fee Related
- 2001-12-19 CA CA2432303A patent/CA2432303C/en not_active Expired - Fee Related
- 2001-12-19 KR KR1020037008409A patent/KR100909665B1/ko not_active IP Right Cessation
- 2001-12-19 JP JP2002565976A patent/JP2004518743A/ja active Pending
- 2001-12-19 CA CA002432799A patent/CA2432799C/en not_active Expired - Fee Related
- 2001-12-19 DE DE60123283T patent/DE60123283T2/de not_active Expired - Lifetime
- 2001-12-19 DK DK01994323T patent/DK1353916T3/da active
- 2001-12-19 JP JP2002557938A patent/JP4210520B2/ja not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005609A patent/MXPA03005609A/es active IP Right Grant
- 2001-12-19 RU RU2003122209/04A patent/RU2355688C2/ru not_active IP Right Cessation
- 2001-12-19 CA CA002432131A patent/CA2432131C/en not_active Expired - Fee Related
- 2001-12-19 DE DE60119776T patent/DE60119776T2/de not_active Expired - Lifetime
- 2001-12-19 EP EP01994323A patent/EP1353916B1/de not_active Expired - Lifetime
- 2001-12-19 HU HU0400908A patent/HUP0400908A3/hu unknown
- 2001-12-19 AT AT01993360T patent/ATE326461T1/de active
- 2001-12-19 NZ NZ526470A patent/NZ526470A/xx not_active IP Right Cessation
- 2001-12-19 US US10/027,001 patent/US6653301B2/en not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005606A patent/MXPA03005606A/es active IP Right Grant
- 2001-12-19 AT AT01271061T patent/ATE327989T1/de active
- 2001-12-19 CN CNB018221025A patent/CN100436452C/zh not_active Expired - Fee Related
- 2001-12-19 JP JP2002567928A patent/JP4234435B2/ja not_active Expired - Fee Related
- 2001-12-19 BR BR0116411-2A patent/BR0116411A/pt not_active IP Right Cessation
- 2001-12-19 ES ES01985059T patent/ES2265446T3/es not_active Expired - Lifetime
- 2001-12-19 US US10/026,966 patent/US20030105090A1/en not_active Abandoned
- 2001-12-19 IL IL15640701A patent/IL156407A0/xx not_active IP Right Cessation
- 2001-12-19 SI SI200130722T patent/SI1355905T1/sl unknown
- 2001-12-19 KR KR1020037008397A patent/KR100947185B1/ko not_active IP Right Cessation
- 2001-12-19 HU HU0400842A patent/HUP0400842A2/hu unknown
- 2001-12-19 HU HU0400638A patent/HUP0400638A2/hu unknown
- 2001-12-19 EP EP10184271A patent/EP2264028A1/de not_active Withdrawn
- 2001-12-19 AT AT01985059T patent/ATE326460T1/de active
- 2001-12-19 ES ES01993360T patent/ES2265450T3/es not_active Expired - Lifetime
- 2001-12-19 IL IL15636901A patent/IL156369A0/xx active IP Right Grant
- 2001-12-19 IL IL15640801A patent/IL156408A0/xx unknown
- 2001-12-19 US US10/026,975 patent/US6653300B2/en not_active Expired - Fee Related
- 2001-12-19 EP EP01994510A patent/EP1345927B1/de not_active Expired - Lifetime
- 2001-12-19 HU HU0400641A patent/HUP0400641A3/hu unknown
- 2001-12-19 EP EP01271061A patent/EP1345922B1/de not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/049139 patent/WO2002066461A1/en active IP Right Grant
- 2001-12-19 AT AT01994323T patent/ATE340172T1/de active
- 2001-12-19 HU HU0400639A patent/HUP0400639A3/hu unknown
- 2001-12-19 ES ES06011799T patent/ES2375491T3/es not_active Expired - Lifetime
- 2001-12-19 ES ES01271061T patent/ES2266095T3/es not_active Expired - Lifetime
- 2001-12-19 AU AU2002234047A patent/AU2002234047A1/en not_active Abandoned
- 2001-12-19 WO PCT/US2001/051031 patent/WO2002062789A1/en active IP Right Grant
- 2001-12-19 MX MXPA03005610A patent/MXPA03005610A/es active IP Right Grant
- 2001-12-19 AP APAP/P/2003/002825A patent/AP2003002825A0/en unknown
- 2001-12-19 MX MXPA03005605A patent/MXPA03005605A/es active IP Right Grant
- 2001-12-19 NZ NZ526473A patent/NZ526473A/en not_active IP Right Cessation
- 2001-12-19 PT PT01994323T patent/PT1353916E/pt unknown
- 2001-12-19 KR KR1020037008427A patent/KR100875091B1/ko not_active IP Right Cessation
- 2001-12-19 DK DK01271061T patent/DK1345922T3/da active
- 2001-12-19 KR KR1020037008385A patent/KR100889246B1/ko not_active IP Right Cessation
- 2001-12-19 WO PCT/US2001/049401 patent/WO2002057259A2/en active Application Filing
- 2001-12-19 ES ES01994510T patent/ES2265452T3/es not_active Expired - Lifetime
- 2001-12-19 US US10/026,967 patent/US6989385B2/en not_active Expired - Fee Related
- 2001-12-19 NZ NZ526471A patent/NZ526471A/en not_active IP Right Cessation
- 2001-12-19 DE DE60126828T patent/DE60126828T2/de not_active Expired - Lifetime
- 2001-12-19 DE DE60119775T patent/DE60119775T2/de not_active Expired - Lifetime
- 2001-12-19 IL IL15636801A patent/IL156368A0/xx not_active IP Right Cessation
- 2001-12-19 KR KR1020037008387A patent/KR100843114B1/ko not_active IP Right Cessation
- 2001-12-19 KR KR10-2003-7008415A patent/KR20030061858A/ko active IP Right Grant
- 2001-12-19 CA CA002432129A patent/CA2432129C/en not_active Expired - Fee Related
- 2001-12-19 IL IL15638901A patent/IL156389A0/xx active IP Right Grant
- 2001-12-19 BR BR0116493-7A patent/BR0116493A/pt not_active IP Right Cessation
- 2001-12-19 CN CNB01822105XA patent/CN100406454C/zh not_active Expired - Fee Related
- 2001-12-19 JP JP2002551561A patent/JP4160389B2/ja not_active Expired - Fee Related
- 2001-12-19 EP EP01273861A patent/EP1355905B1/de not_active Expired - Lifetime
- 2001-12-19 EP EP06011799A patent/EP1702920B1/de not_active Expired - Lifetime
- 2001-12-19 CA CA002432222A patent/CA2432222C/en not_active Expired - Fee Related
- 2001-12-19 EP EP01993360A patent/EP1345926B1/de not_active Expired - Lifetime
- 2001-12-19 MX MXPA03005608A patent/MXPA03005608A/es not_active Application Discontinuation
- 2001-12-19 JP JP2002563142A patent/JP4160395B2/ja not_active Expired - Fee Related
- 2001-12-19 AU AU2001297619A patent/AU2001297619B2/en not_active Ceased
- 2001-12-19 AT AT01273861T patent/ATE354573T1/de active
- 2001-12-19 CA CA002432223A patent/CA2432223C/en not_active Expired - Fee Related
- 2001-12-19 AP APAP/P/2003/002816A patent/AP1588A/en active
- 2001-12-19 DK DK01273861T patent/DK1355905T3/da active
- 2001-12-19 AT AT06011799T patent/ATE528303T1/de not_active IP Right Cessation
- 2001-12-19 NZ NZ526469A patent/NZ526469A/en not_active IP Right Cessation
- 2001-12-19 MX MXPA03005607A patent/MXPA03005607A/es active IP Right Grant
- 2001-12-19 NZ NZ526472A patent/NZ526472A/en not_active IP Right Cessation
- 2001-12-19 PT PT01271061T patent/PT1345922E/pt unknown
- 2001-12-19 WO PCT/US2001/050312 patent/WO2002068415A1/en active IP Right Grant
- 2001-12-19 US US10/026,992 patent/US7625913B2/en not_active Expired - Fee Related
- 2001-12-19 CN CNA018221033A patent/CN1486310A/zh active Pending
- 2001-12-20 US US10/034,019 patent/US6727251B2/en not_active Expired - Fee Related
- 2001-12-20 MX MXPA03005611A patent/MXPA03005611A/es unknown
- 2001-12-20 EP EP01991439A patent/EP1345928B1/de not_active Expired - Lifetime
- 2001-12-20 AT AT01994347T patent/ATE326463T1/de not_active IP Right Cessation
- 2001-12-20 AR ARP010105963A patent/AR040925A1/es active IP Right Grant
- 2001-12-20 CA CA002432872A patent/CA2432872C/en not_active Expired - Fee Related
- 2001-12-20 KR KR10-2003-7008364A patent/KR20030061463A/ko active IP Right Grant
- 2001-12-20 DE DE60126658T patent/DE60126658T2/de not_active Expired - Lifetime
- 2001-12-20 JP JP2002551562A patent/JP2004516292A/ja active Pending
- 2001-12-20 CA CA002432132A patent/CA2432132C/en not_active Expired - Fee Related
- 2001-12-20 WO PCT/US2001/049594 patent/WO2002059112A2/en active IP Right Grant
- 2001-12-20 NZ NZ526474A patent/NZ526474A/en unknown
- 2001-12-20 AR ARP010105960A patent/AR042397A1/es active IP Right Grant
- 2001-12-20 KR KR10-2003-7008366A patent/KR20030061464A/ko not_active Application Discontinuation
- 2001-12-20 WO PCT/US2001/049585 patent/WO2002050066A2/en active IP Right Grant
- 2001-12-20 US US10/034,683 patent/US6656939B2/en not_active Expired - Fee Related
- 2001-12-20 AR ARP010105962A patent/AR042169A1/es active IP Right Grant
- 2001-12-20 MX MXPA03005612A patent/MXPA03005612A/es not_active Application Discontinuation
- 2001-12-20 AT AT01991439T patent/ATE353890T1/de not_active IP Right Cessation
- 2001-12-20 AU AU3116602A patent/AU3116602A/xx active Pending
- 2001-12-20 AR ARP010105961A patent/AR042398A1/es unknown
- 2001-12-20 DE DE60119777T patent/DE60119777T2/de not_active Expired - Lifetime
- 2001-12-20 AU AU2002246754A patent/AU2002246754B2/en not_active Ceased
- 2001-12-20 JP JP2002559414A patent/JP2004517927A/ja active Pending
- 2001-12-20 NZ NZ526475A patent/NZ526475A/en unknown
- 2001-12-20 AU AU2002231166A patent/AU2002231166B2/en not_active Ceased
- 2001-12-20 EP EP01994347A patent/EP1345929B1/de not_active Expired - Lifetime
- 2001-12-21 MY MYPI20015823A patent/MY140377A/en unknown
- 2001-12-25 TW TW090131846A patent/TWI290551B/zh not_active IP Right Cessation
- 2001-12-25 TW TW095139649A patent/TWI313269B/zh not_active IP Right Cessation
2003
- 2003-06-10 IL IL156369A patent/IL156369A/en not_active IP Right Cessation
- 2003-06-11 IL IL156389A patent/IL156389A/en not_active IP Right Cessation
- 2003-06-12 NO NO20032671A patent/NO20032671L/no not_active Application Discontinuation
- 2003-06-12 NO NO20032670A patent/NO328537B1/no not_active IP Right Cessation
- 2003-06-13 NO NO20032703A patent/NO328501B1/no not_active IP Right Cessation
- 2003-06-13 NO NO20032704A patent/NO330527B1/no not_active IP Right Cessation
- 2003-06-16 NO NO20032736A patent/NO20032736L/no unknown
- 2003-08-01 US US10/632,428 patent/US7531536B2/en not_active Expired - Fee Related
- 2003-11-25 US US10/722,374 patent/US20040157893A1/en not_active Abandoned
- 2003-12-15 US US10/736,426 patent/US7087603B2/en not_active Expired - Fee Related
2004
- 2004-02-10 US US10/775,699 patent/US7427681B2/en not_active Expired - Fee Related
- 2004-02-12 HK HK04100960A patent/HK1059776A1/xx not_active IP Right Cessation
- 2004-03-15 HK HK04101883A patent/HK1060347A1/xx not_active IP Right Cessation
- 2004-03-15 HK HK04101882A patent/HK1060346A1/xx not_active IP Right Cessation
- 2004-03-16 HK HK04101940A patent/HK1060557A1/xx not_active IP Right Cessation
- 2004-03-16 HK HK04101941A patent/HK1062433A1/xx not_active IP Right Cessation
- 2004-03-17 HK HK04101996A patent/HK1060349A1/xx not_active IP Right Cessation
- 2004-03-22 HK HK04102099A patent/HK1061389A1/xx not_active IP Right Cessation
- 2004-07-27 HK HK04105510.6A patent/HK1062565A1/xx not_active IP Right Cessation
- 2004-12-17 JP JP2004366925A patent/JP2005097322A/ja not_active Withdrawn
2006
- 2006-03-21 AU AU2006201267A patent/AU2006201267B2/en not_active Ceased
- 2006-12-20 CY CY20061101823T patent/CY1106297T1/el unknown
2008
- 2008-04-01 JP JP2008095581A patent/JP2008189682A/ja not_active Withdrawn
- 2008-04-01 JP JP2008095584A patent/JP2008260767A/ja not_active Withdrawn
- 2008-04-03 JP JP2008097620A patent/JP2008222719A/ja active Pending
- 2008-04-04 JP JP2008098506A patent/JP2008189687A/ja active Pending
- 2008-04-25 US US12/109,598 patent/US8304414B2/en not_active Expired - Fee Related
- 2008-05-07 JP JP2008121724A patent/JP2008247920A/ja active Pending
- 2008-05-07 JP JP2008121727A patent/JP2008247921A/ja active Pending
- 2008-05-07 JP JP2008121723A patent/JP2008201808A/ja active Pending
2009
- 2009-04-17 JP JP2009101481A patent/JP5249842B2/ja not_active Expired - Fee Related
- 2009-08-21 US US12/545,347 patent/US7982037B2/en not_active Expired - Fee Related
- 2009-09-14 JP JP2009212566A patent/JP2009286805A/ja not_active Withdrawn
2010
- 2010-12-07 IL IL209827A patent/IL209827A0/en unknown
2012
- 2012-09-28 US US13/631,488 patent/US8697698B2/en not_active Expired - Fee Related
2013
- 2013-07-19 JP JP2013150948A patent/JP2013213068A/ja active Pending
- 2013-12-24 US US14/139,889 patent/US20140187772A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1345929B1 (de)	2006-05-17
CN102250071A (zh)	2011-11-23
CN1486311A (zh)	2004-03-31
ES2266095T3 (es)	2007-03-01
MY140377A (en)	2009-12-31
JP2005097322A (ja)	2005-04-14
HK1060557A1 (en)	2004-08-13
IL156369A (en)	2011-02-28
JP2008189682A (ja)	2008-08-21
HUP0400908A2 (hu)	2004-07-28
US7087603B2 (en)	2006-08-08
US20050038023A1 (en)	2005-02-17
JP4234435B2 (ja)	2009-03-04
NO20032670D0 (no)	2003-06-12
WO2002059111A3 (en)	2003-01-09
DE60120219D1 (de)	2006-07-06
EP1353916A2 (de)	2003-10-22
US7982037B2 (en)	2011-07-19
DE60119774D1 (de)	2006-06-22
ATE327989T1 (de)	2006-06-15
ES2280313T3 (es)	2007-09-16
TW200716617A (en)	2007-05-01
JP2004518743A (ja)	2004-06-24
US8697698B2 (en)	2014-04-15
PT1345922E (pt)	2006-09-29
CA2432222C (en)	2008-07-29
CA2432872C (en)	2008-09-23
CA2432223C (en)	2008-05-20
EP1345925A2 (de)	2003-09-24
ES2272567T3 (es)	2007-05-01
DE60119774T2 (de)	2007-05-16
ATE353890T1 (de)	2007-03-15
NO330527B1 (no)	2011-05-09
DE60126658T2 (de)	2007-11-22
AP2003002816A0 (en)	2003-06-30
US20030022885A1 (en)	2003-01-30
AU2002246754B2 (en)	2006-06-08
JP4160392B2 (ja)	2008-10-01
CA2432132A1 (en)	2002-08-01
WO2002057259A2 (en)	2002-07-25
RU2355688C2 (ru)	2009-05-20
HK1061389A1 (en)	2004-09-17
EP1345926B1 (de)	2006-05-17
CA2432799A1 (en)	2002-06-27
NO20032671D0 (no)	2003-06-12
CN100436452C (zh)	2008-11-26
HUP0400639A2 (hu)	2004-06-28
WO2002059111A2 (en)	2002-08-01
AU2001297619B2 (en)	2006-06-08
CA2432129C (en)	2008-08-26
DE60119776T2 (de)	2007-05-16
CN1549812A (zh)	2004-11-24
KR100875091B1 (ko)	2008-12-22
US20030055068A1 (en)	2003-03-20
DE60119775T2 (de)	2007-05-10
JP2008247920A (ja)	2008-10-16
US20080287444A1 (en)	2008-11-20
CA2432872A1 (en)	2002-06-27
PL210066B1 (pl)	2011-11-30
KR20030061466A (ko)	2003-07-18
ATE326460T1 (de)	2006-06-15
EP1355905B1 (de)	2007-02-21
EP1355905A1 (de)	2003-10-29
IL156369A0 (en)	2004-01-04
JP2009286805A (ja)	2009-12-10
NO20032704L (no)	2003-08-21
ES2375491T3 (es)	2012-03-01
US6653300B2 (en)	2003-11-25
NO20032671L (no)	2003-08-18
IL156368A0 (en)	2004-01-04
PT1353916E (pt)	2007-01-31
US20040132781A1 (en)	2004-07-08
SI1355905T1 (sl)	2007-08-31
US20040157893A1 (en)	2004-08-12
NO20032703D0 (no)	2003-06-13
NZ526474A (en)	2005-10-28
PL363246A1 (en)	2004-11-15
US20040214814A1 (en)	2004-10-28
WO2002050066A3 (en)	2003-01-23
KR20030061467A (ko)	2003-07-18
DE60123283D1 (de)	2006-11-02
ATE354573T1 (de)	2007-03-15
US20030036543A1 (en)	2003-02-20
WO2002059112A2 (en)	2002-08-01
BR0116411A (pt)	2003-11-11
AU3116602A (en)	2002-07-01
US7427681B2 (en)	2008-09-23
HK1060349A1 (en)	2004-08-06
WO2002068415A1 (en)	2002-09-06
HUP0400842A2 (hu)	2004-07-28
TWI313269B (en)	2009-08-11
HK1060347A1 (en)	2004-08-06
HK1059776A1 (en)	2004-07-16
US20030105090A1 (en)	2003-06-05
JP2013213068A (ja)	2013-10-17
KR20030061468A (ko)	2003-07-18
EP1345927B1 (de)	2006-05-17
EP1345922A1 (de)	2003-09-24
KR20030061858A (ko)	2003-07-22
WO2002050066A2 (en)	2002-06-27
CN100406454C (zh)	2008-07-30
NZ526473A (en)	2005-06-24
US6664247B2 (en)	2003-12-16
JP2004516292A (ja)	2004-06-03
US20030004164A1 (en)	2003-01-02
CA2432303A1 (en)	2002-08-29
IL156407A0 (en)	2004-01-04
NO20032736D0 (no)	2003-06-16
MXPA03005611A (es)	2003-10-06
MXPA03005608A (es)	2003-10-06
TWI290551B (en)	2007-12-01
JP2008201808A (ja)	2008-09-04
EP1702920A1 (de)	2006-09-20
EP1345928A2 (de)	2003-09-24
RU2003122209A (ru)	2005-02-10
MXPA03005610A (es)	2003-10-06
DE60119776D1 (de)	2006-06-22
JP2004519479A (ja)	2004-07-02
WO2002057259A3 (en)	2003-04-24
JP2008260767A (ja)	2008-10-30
MXPA03005605A (es)	2003-10-06
IL156389A (en)	2011-01-31
JP2004517926A (ja)	2004-06-17
HK1062565A1 (en)	2004-11-12
DE60120219T2 (de)	2007-04-12
NZ526469A (en)	2005-10-28
DE60126828T2 (de)	2007-11-08
JP2004516291A (ja)	2004-06-03
EP2264028A1 (de)	2010-12-22
JP2004518703A (ja)	2004-06-24
HUP0400639A3 (en)	2010-03-29
ATE326463T1 (de)	2006-06-15
EP1345926A2 (de)	2003-09-24
KR20030061463A (ko)	2003-07-18
NZ526468A (en)	2004-03-26
WO2002050065A3 (en)	2002-10-24
DE60126658D1 (de)	2007-03-29
EP1353916B1 (de)	2006-09-20
NO20032670L (no)	2003-08-15
AU2002231166B2 (en)	2008-02-21
MXPA03005612A (es)	2003-10-06
EP1345922B1 (de)	2006-05-31
US6656939B2 (en)	2003-12-02
BR0116493A (pt)	2003-09-30
KR100889246B1 (ko)	2009-03-19
KR20030061857A (ko)	2003-07-22
ES2265446T3 (es)	2007-02-16
MXPA03005607A (es)	2003-10-06
WO2002066461A1 (en)	2002-08-29
HUP0400641A2 (hu)	2004-06-28
NZ526470A (en)	2006-03-31
NO328537B1 (no)	2010-03-15
US20030004161A1 (en)	2003-01-02
WO2002062789A1 (en)	2002-08-15
NZ526471A (en)	2005-08-26
CN100340555C (zh)	2007-10-03
US20130096128A1 (en)	2013-04-18
CN1487933A (zh)	2004-04-07
KR100843114B1 (ko)	2008-07-02
ATE340172T1 (de)	2006-10-15
CA2432131C (en)	2008-07-08
PL363244A1 (en)	2004-11-15
EP1702920B1 (de)	2011-10-12
AP2003002825A0 (en)	2003-09-30
AU2006201267B2 (en)	2010-07-29
ATE326461T1 (de)	2006-06-15
HUP0400908A3 (en)	2010-03-29
HUP0400638A2 (hu)	2004-06-28
MXPA03005606A (es)	2003-10-06
DE60123283T2 (de)	2007-04-12
NZ526475A (en)	2005-06-24
CA2432129A1 (en)	2002-07-25
AR040925A1 (es)	2005-04-27
US20030078275A1 (en)	2003-04-24
JP4210520B2 (ja)	2009-01-21
US8304414B2 (en)	2012-11-06
EP1345928B1 (de)	2007-02-14
AU2006201267A1 (en)	2006-04-27
JP2004517894A (ja)	2004-06-17
KR20030061465A (ko)	2003-07-18
US7625913B2 (en)	2009-12-01
JP2008189687A (ja)	2008-08-21
CN100408573C (zh)	2008-08-06
JP2004517927A (ja)	2004-06-17
JP4160389B2 (ja)	2008-10-01
JP2008222719A (ja)	2008-09-25
KR20030061464A (ko)	2003-07-18
DE60119775D1 (de)	2006-06-22
KR100947185B1 (ko)	2010-03-15
DE60126828D1 (de)	2007-04-05
DK1345922T3 (da)	2006-09-18
CY1106297T1 (el)	2011-10-12
PL210414B1 (pl)	2012-01-31
NO20032703L (no)	2003-08-19
HK1060346A1 (en)	2004-08-06
MXPA03005609A (es)	2003-10-06
IL156408A0 (en)	2004-01-04
ES2265450T3 (es)	2007-02-16
CN1486310A (zh)	2004-03-31
EP1345929A2 (de)	2003-09-24
JP2008247921A (ja)	2008-10-16
KR100909665B1 (ko)	2009-07-29
DK1353916T3 (da)	2007-01-29
WO2002050065A2 (en)	2002-06-27
NO20032736L (no)	2003-08-18
SI1353916T1 (sl)	2007-02-28
EP1345927A1 (de)	2003-09-24
US7531536B2 (en)	2009-05-12
NO328501B1 (no)	2010-03-01
CA2432223A1 (en)	2002-09-06
CA2432799C (en)	2008-08-19
EP1345925B1 (de)	2006-05-17
PT1355905E (pt)	2007-05-31
US6727251B2 (en)	2004-04-27
AR042398A1 (es)	2005-06-22
IL209827A0 (en)	2011-02-28
WO2002059112A3 (en)	2003-02-06
ATE528303T1 (de)	2011-10-15
JP2009155352A (ja)	2009-07-16
HK1062433A1 (en)	2004-11-05
JP4160395B2 (ja)	2008-10-01
US6653301B2 (en)	2003-11-25
AR042169A1 (es)	2005-06-15
ES2265452T3 (es)	2007-02-16
CA2432131A1 (en)	2002-08-01
AU2002234047A1 (en)	2002-07-01
CA2432222A1 (en)	2002-08-15
DK1355905T3 (da)	2007-06-18
DE60119777D1 (de)	2006-06-22
US20140187772A1 (en)	2014-07-03
CN1486312A (zh)	2004-03-31
US20090312543A1 (en)	2009-12-17
HUP0400641A3 (en)	2010-03-29
CA2432303C (en)	2010-04-13
DE60119777T2 (de)	2007-05-03
NZ526472A (en)	2004-04-30
AU2002255452B2 (en)	2006-06-08
CA2432132C (en)	2008-07-29
AR042397A1 (es)	2005-06-22
AP1588A (en)	2006-03-06
US6989385B2 (en)	2006-01-24
US20040167141A1 (en)	2004-08-26
IL156389A0 (en)	2004-01-04
NO20032704D0 (no)	2003-06-13
JP5249842B2 (ja)	2013-07-31

Publication	Publication Date	Title
ATE294797T1 (de)	2005-05-15	Pyrazolverbindungen als protein-kinasehemmer
ATE326460T1 (de)	2006-06-15	Pyrazolverbindungen als proteinkinasehemmer
ATE445613T1 (de)	2009-10-15	Indolylmaleimidderivative als proteinkinase-c- inhibitoren
DK1317448T4 (da)	2011-05-30	Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer

Legal Events

Date	Code	Title	Description
2007-05-15	UEP	Publication of translation of european patent specification	Ref document number: 1345927 Country of ref document: EP

Date

Code

Title

Description

2007-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1345927

Country of ref document: EP